Meeting
2018 ASCO Annual Meeting
Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).
Presenter
Jonathan E. Rosenberg, MD
Memorial Sloan Kettering Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02091999
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4504)
DOI
10.1200/JCO.2018.36.15_suppl.4504
Abstract #
4504
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Breakthrough
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Speaker: Eiji Kikuchi, PhD
Videos & Slides
2024 ASCO Annual Meeting
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Speaker: Shilpa Gupta, MD
Videos & Slides
2024 ASCO Annual Meeting
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
Speaker: Daniel P. Petrylak, MD
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.
Speaker: Michiel Simon Van Der Heijden, MD, PhD